BOSTON, September 26, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, ...

In the DH 2000 test, the degradation rates of Vertex N modules was -0.87% and -0.96%, less than -1%. In performance tests, Trina Solar’s modules scored high in LeTId, module efficiency and PTC.

Vertex’s press releases are available at www.vrtx.com. (VRTX-WEB) CONTACT: Vertex Pharmaceuticals Incorporated Lora Pike, 617-444-6755 Director, Investor Relations ...

For the interim analysis of its Phase II study combining VX-809 and Kalydeco (ivacaftor) in cystic fibrosis patients homozygous for the F508del mutation, Vertex Pharmaceuticals Inc. presented data ...